The nation of Zimbabwe has rejected a substantial US health deal worth 367 million US dollars (£272m) spanning five years due to Washington's request for sensitive biological samples.
The decision was revealed following a internal memorandum from December was leaked, which showed Head of State Emmerson Mnangagwa deemed the arrangement was "skewed".
An official representative has since clarified that the United States was requesting health data for research and commercial gain while was not willing to share the resulting advantages from future vaccines.
"We will now turn to the challenging and unfortunate process of ending our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had donated over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for continued negotiations to reach a agreement acceptable to both sides so the country's critical HIV treatment initiative can proceed.
Broader Implications
This rejection comes after a similar situation in neighbouring Kenya, where a court halted a similar deal with the US after concerns were raised about the safety of citizens' medical information.
After returning to office last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump argued its spending was "wasteful" and his administration was pursuing direct bilateral deals to enhance openness and responsibility.
Based on reports, Sixteen African countries have so far agreed to these new agreements, constituting more than $18.3bn in committed funds.
Details of the Rejected Deal
The funds for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration might have yielded significant advantages for Zimbabwean communities, particularly the 1.2 million presently receiving antiretroviral therapy through US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to provide its biological resources and data for a long time, without any corresponding promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"Effectively, our nation would provide the raw materials for medical research without any assurance that the end products would be accessible to our citizens should a new disease outbreak arise."
Sovereignty and International Frameworks
He also said that the American exit from the global health body and its push of bilateral deals were undermining frameworks previously set up through the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to deal with future global health emergencies.
"This framework is designed to guarantee that when a nation provides its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the funds to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to continued discussions with our US partners on how subsequent collaboration might be designed in a manner that honours the sovereignty and dignity of both nations."
Medical Community Response
Medical experts stated it understood the government's concerns, but urged that negotiations must proceed since a large portion of the country's HIV programmes depended on external financing.
"Where specific concerns arise, such as those relating to information security or agreement terms, these can often be resolved through detailed discussion and mutually agreed protections," it commented.
This impasse highlights the ongoing challenges between accepting crucial foreign assistance and safeguarding local interests in an increasingly data-driven world.